Media coverage about Uroplasty (NASDAQ:UPI) has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Uroplasty earned a news impact score of 0.05 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 44.8783412529959 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Uroplasty (NASDAQ:UPI) opened at $1.22 on Thursday. The company has a market capitalization of $27.68, a P/E ratio of -4.07 and a beta of -1.26. Uroplasty has a one year low of $1.05 and a one year high of $4.05.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/01/25/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-uroplasty-upi-stock-price.html.
Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.